Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31653832 | 1.00 | KEAP1 (0.43) | KEAP1CA1CA12CA9GAA | |
| SCHEMBL6887707 | 0.81 | CA12 (0.48) | CA1CA12CA9GAAHSD17B10 | |
| SCHEMBL317626 | 0.80 | CA12 (0.42) | CA1CA12CA9GAATP53 | |
| SCHEMBL1464604 | 0.79 | CA12 (0.41) | CA1CA12CA9GAAHSD17B10 | |
| SCHEMBL610788 | 0.79 | CA12 (0.41) | CA1CA12CA9GAATP53 | |
| SCHEMBL29549481 | 0.78 | SCN2A (0.54) | KEAP1CA1CA12CA9GAA | |
| SCHEMBL10627311 | 0.78 | MCL1 (0.42) | CA1CA12CA9GAATP53 | |
| SCHEMBL9596295 | 0.76 | CA12 (0.39) | CA1CA12CA9GAATP53 | |
| SCHEMBL4256629 | 0.76 | GAA (0.41) | CA1CA12CA9GAATP53 | |
| SCHEMBL29720997 | 0.76 | KDM4E (0.46) | KEAP1KDM4EHPGDP2RX7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116761810-A | Imaging and targeting of programmed death ligand-1 (PD-L1) expression | 约翰霍普金斯大学 | 2023-09-15 | — | — | CN | claimed |
| US-20230271923-A1 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSTY | 2023-08-31 | — | — | US | claimed |
| EP-4192524-A2 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | The Johns Hopkins University (US) | 2023-06-14 | — | — | EP | claimed |
| US-11607466-B2 | Tumor and immune cell imaging based on PD-L1 expression | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-03-21 | — | — | US | claimed |
| WO-2022032100-A2 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-02-10 | — | — | WO | claimed |
| EP-3558395-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | The Johns Hopkins University (US) | 2019-10-30 | — | — | EP | claimed |
| CN-110366432-A | Tumour and immunocyte imaging based on PD-L1 expression | 约翰霍普金斯大学 | 2019-10-22 | — | — | CN | claimed |
| US-20190314531-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | THE JOHNS HOPKINS UNIVERSITY | 2019-10-17 | — | — | US | claimed |
| WO-2018119313-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-28 | — | — | WO | claimed |
| US-12583913-B2 | Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same | CHURCH WILLIAM R (US) | 2026-03-24 | — | — | US | disclosed |
| US-20240166730-A1 | ANTIBODY SPECIFIC TO STAPHYLOCOCCUS AUREUS, THERAPEUTIC METHOD AND DETECTION METHOD USING SAME | CHURCH WILLIAM R (US) | 2024-05-23 | — | — | US | disclosed |
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-02-27 | — | — | US | disclosed |
| CN-116761810-A | Imaging and targeting of programmed death ligand-1 (PD-L1) expression | 约翰霍普金斯大学 | 2023-09-15 | — | — | CN | disclosed |
| US-20230271923-A1 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSTY | 2023-08-31 | — | — | US | disclosed |
| WO-2010139075-A1 | SYNTHESIS AND USE OF RADIOLABELLED INSULIN ANALOGUES | MCMASTER UNIVERSITY (CA) | 2010-12-09 | — | — | WO | disclosed |
| US-20100034800-A1 | COMPOSITIONS FOR DETECTING CELL DEATH AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100015058-A1 | RADIOLABELED BBN-RGD HETERODIMERS FOR CANCER TARGETING | STANFORD UNIVERSITY (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009138763-A1 | FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286992-A1 | FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20080267882-A1 | Multimeric RGD (arginine-glycine-aspartic acid (Arg-Gly-Asp)) peptide; positron emission tomography; angiogenesis; kits | STANFORD UNIVERSITY (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583913-B2 | Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same | IGSF11, VSIG8, VARS1 | KEAP1 3943/4885CA1 4857/4885CA12 4853/4885 |
| US-20090286992-A1 | FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES | RARB, RARG, RARA | KEAP1 3427/4885CA1 638/4885CA12 316/4885 |
| US-11607466-B2 | Tumor and immune cell imaging based on PD-L1 expression | CD274, PDCD1LG2, PDCD1 | KEAP1 1573/4885CA1 1849/4885CA12 633/4885 |
| US-20190314531-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | CD274, PDCD1LG2, PDCD1 | KEAP1 1573/4885CA1 1849/4885CA12 633/4885 |
| US-20230271923-A1 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | CD274, PDCD1LG2, PDCD1 | KEAP1 2566/4885CA1 1465/4885CA12 694/4885 |
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | FOLH1, PSMA3, PSMA7 | KEAP1 3359/4885CA1 336/4885CA12 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.